Form 8-K NPS PHARMACEUTICALS INC For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Canaccord Keeps NPS Pharma (NPSP) at 'Buy'; Some Centers Slower to Put Patients on Gattex
November 11, 2014 11:07 AM ESTCanaccord Genuity affirms NPS Pharmaceuticals (Nasdaq: NPSP) at Buy with a price target of $42 following Q3 results reported Monday night.
Analyst John Newman noted that Gattex growth of about 18.6 percent over Q2 was flat with expectations, but guidance of $100 to... More
NPS Pharmaceuticals (NPSP) Misses Q3 EPS by 3c
November 10, 2014 4:07 PM ESTNPS Pharmaceuticals (NASDAQ: NPSP) reported Q3 EPS of ($0.02), $0.03 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $57.2 million versus the consensus estimate of $59.5 million.
For earnings history and earnings-related data on NPS Pharmaceuticals (NPSP) click here.
... More


